Diana Boghozian
Nurse Practitioner · Glendale, CANPI 1316545239
Payments from drug & device makers
Across 151 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$767
- Amgen$580
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$532
- Lilly USA, LLC$294
- Optinose US, Inc.$216
- Novartis$154
- plus $874 from 16 others
What the payments were for
- Food & beverage$3,417100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 32 | $767 |
| Amgen(2 entities) | 24 | $580 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $532 |
| Lilly USA, LLC | 11 | $294 |
| Optinose US, Inc. | 10 | $216 |
| Novartis | 7 | $154 |
| Sunovion Pharmaceuticals Inc. | 7 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| GSK | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $86 |
| AbbVie | 3 | $73 |
| AstraZeneca | 3 | $64 |
| Merck | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 2 | $55 |
| Boehringer Ingelheim | 2 | $50 |
| Novo Nordisk | 2 | $32 |
| Bayer | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Phadia US Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,417 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 86 | $116,392 |
| JardianceEmpagliflozin | 178 | $112,150 |
| VascepaIcosapent Ethyl | 156 | $56,308 |
| TrulicityDulaglutide | 34 | $44,780 |
| Diclofenac Sodium | 66 | $35,741 |
| MounjaroTirzepatide | 32 | $31,419 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $31,122 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $25,661 |
| ProliaDenosumab | 13 | $21,900 |
| EntrestoSacubitril/Valsartan | 31 | $21,271 |
| EliquisApixaban | 29 | $19,625 |
| Repatha SureclickEvolocumab | 34 | $17,406 |
| TrulancePlecanatide | 29 | $16,523 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $12,262 |
| Diflorasone Diacetate | 20 | $11,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $50 | $120,762194 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $294 | $76,19966 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $88 | $39,59770 claims |
| MerckJanumet, Januvia | $63 | $32,12853 claims |
| AmgenProlia | $580 | $21,90013 claims |
| NovartisEntresto | $154 | $21,27131 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $532 | $16,52329 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $23 | $10,09222 claims |
| AstraZenecaFarxiga | $64 | $6,22511 claims |
| AbbVieLinzess | $73 | $5,90211 claims |
| Esperion Therapeutics, Inc.Nexlizet | $767 | $5,56114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Glendale
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.